The United States Food and Drug Administration (FDA) has granted orphan drug status to Reata Pharmaceuticals, Inc. for their agent RTA 402 in the treatment of pancreatic cancer.

RTA 402 is an antioxidant inflammation modulator (AIM) that reduces inflammation and oxidative stress.

RTA 402 is currently in a Phase I/II clinical trial.

Recommended Articles

Image placeholder title

What Should Women Know About Bladder Cancer

Michael O’Donnell, MD Director of Urologic Oncology, University of Iowa Hospitals and Clinics

ASCO 2019

Liquid Biopsy Detects Disease Progression Much Earlier Than Imaging

What if a simple blood test could quickly determine when chemotherapy was ineffective and prevent its unnecessary use?